Patents by Inventor Roman Rariy
Roman Rariy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20200345722Abstract: An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opioids. In the preferred embodiment, the drug is modified to increase its lipophilicity by forming a salt between the drug and one or more fatty acids wherein the concentration of the one or more fatty acids is one to 15 times the molar amount of the active agent, preferably two to ten times the molar amount of the active agent. In one embodiment the modified drug is homogeneously dispersed within microparticles composed of a material that is either slowly soluble or not soluble in water. In some embodiments the drug containing microparticles or drug particles are coated with one or more coating layers, where at least one coating is water insoluble and preferably organic solvent insoluble.Type: ApplicationFiled: July 17, 2020Publication date: November 5, 2020Inventors: Jane HIRSH, Alison FLEMING, Roman RARIY, Alexander KLIBANOV
-
Publication number: 20200093819Abstract: An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opiods. In the preferred embodiment, the drug is modified to increase its lipophilicity by forming a salt between the drug and one or more fatty acids wherein the concentration of the one or more fatty acids is one to 15 times the molar amount of the active agent, preferably two to ten times the molar amount of the active agent. In one embodiment the modified drug is homogeneously dispersed within microparticles composed of a material that is either slowly soluble or not soluble in water. In some embodiments the drug containing microparticles or drug particles are coated with one or more coating layers, where at least one coating is water insoluble and preferably organic solvent insoluble.Type: ApplicationFiled: November 27, 2019Publication date: March 26, 2020Inventors: Jane HIRSH, Alison FLEMING, Roman RARIY, Alexander KLIBANOV
-
Patent number: 10525052Abstract: An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opiods. In the preferred embodiment, the drug is modified to increase its lipophilicity by forming a salt between the drug and one or more fatty acids wherein the concentration of the one or more fatty acids is one to 15 times the molar amount of the active agent, preferably two to ten times the molar amount of the active agent. In one embodiment the modified drug is homogeneously dispersed within microparticles composed of a material that is either slowly soluble or not soluble in water. In some embodiments the drug containing microparticles or drug particles are coated with one or more coating layers, where at least one coating is water insoluble and preferably organic solvent insoluble.Type: GrantFiled: August 21, 2017Date of Patent: January 7, 2020Assignee: Collegium Pharmaceutical, Inc.Inventors: Jane Hirsh, Alison Fleming, Roman Rariy, Alexander Klibanov
-
Publication number: 20190167662Abstract: Tamper-resistant pharmaceutical compositions have been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opioids. The tamper-resistant compositions retard the release of drug, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is passes through the GI tract.Type: ApplicationFiled: June 25, 2018Publication date: June 6, 2019Inventors: Roman Rariy, Alison Fleming, Jane C. Hirsh, Said Saim, Ravi K. Varanasi
-
Publication number: 20170360710Abstract: An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opiods. In the preferred embodiment, the drug is modified to increase its lipophilicty by forming a salt between the drug and one or more fatty acids wherein the concentration of the one or more fatty acids is one to 15 times the molar amount of the active agent, preferably two to ten times the molar amount of the active agent. In one embodiment the modified drug is homogeneously dispersed within microparticles composed of a material that is either slowly soluble or not soluble in water. In some embodiments the drug containing microparticles or drug particles are coated with one or more coating layers, where at least one coating is water insoluble and preferably organic solvent insoluble.Type: ApplicationFiled: August 21, 2017Publication date: December 21, 2017Inventors: Jane HIRSH, Alison Fleming, Roman Rariy, Alexander Klibanov
-
Patent number: 9763883Abstract: An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opiods. In the preferred embodiment, the drug is modified to increase its lipophilicity by forming a salt between the drug and one or more fatty acids wherein the concentration of the one or more fatty acids is one to 15 times the molar amount of the active agent, preferably two to ten times the molar amount of the active agent. In one embodiment the modified drug is homogeneously dispersed within microparticles composed of a material that is either slowly soluble or not soluble in water. In some embodiments the drug containing microparticles or drug particles are coated with one or more coating layers, where at least one coating is water insoluble and preferably organic solvent insoluble.Type: GrantFiled: January 3, 2014Date of Patent: September 19, 2017Assignee: COLLEGIUM PHARMACEUTICAL, INC.Inventors: Jane Hirsh, Alison Fleming, Roman Rariy, Alexander Klibanov
-
Patent number: 9682075Abstract: Tamper-resistance pharmaceutical compositions have been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opioids. The tamper-resistant compositions retard the release of drug, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is passes through the GI tract.Type: GrantFiled: June 30, 2014Date of Patent: June 20, 2017Assignee: COLLEGIUM PHARMACEUTICAL, INC.Inventors: Roman Rariy, Alison Fleming, Jane C. Hirsh, Said Saim, Ravi K. Varanasi
-
Publication number: 20150004244Abstract: Tamper-resistance pharmaceutical compositions have been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opioids. The tamper-resistant compositions retard the release of drug, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is passes through the GI tract.Type: ApplicationFiled: June 30, 2014Publication date: January 1, 2015Inventors: Roman RARIY, Alison Fleming, Jane C. Hirsh, Said SAIM, Ravi K. Varanasi
-
Publication number: 20150005332Abstract: Tamper-resistant pharmaceutical compositions have been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opioids. The tamper-resistant compositions retard the release of drug, even if the physical integrity of the formulation is compromised (for example, by chopping with a blade or crushing) and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is passes through the GI tract.Type: ApplicationFiled: July 1, 2014Publication date: January 1, 2015Inventors: Roman RARIY, Alison FLEMING, Jane C. HIRSH, Said SAIM, Ravi K. VARANASI
-
Patent number: 8758813Abstract: An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opioids. In one embodiment, the drug is modified to increase its lipophilicity by forming a salt between the drug and one or more fatty acids wherein the concentration of the one or more fatty acids is one to 15 times the molar amount of the active agent. The abuse-deterrent composition prevents the immediate release of a substantial portion of drug, even if the physical integrity of the formulation is compromised and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is broken down or dissolved gradually within the GI tract by a combination of enzymatic degradation, surfactant action of bile acids, and mechanical erosion.Type: GrantFiled: April 25, 2013Date of Patent: June 24, 2014Assignee: Collegium Pharmaceutical, Inc.Inventors: Jane Hirsh, Alison Fleming, Roman Rariy, Alexander M. Klibanov
-
Publication number: 20140121232Abstract: An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opiods. In the preferred embodiment, the drug is modified to increase its lipophilicity by forming a salt between the drug and one or more fatty acids wherein the concentration of the one or more fatty acids is one to 15 times the molar amount of the active agent, preferably two to ten times the molar amount of the active agent. In one embodiment the modified drug is homogeneously dispersed within microparticles composed of a material that is either slowly soluble or not soluble in water. In some embodiments the drug containing microparticles or drug particles are coated with one or more coating layers, where at least one coating is water insoluble and preferably organic solvent insoluble.Type: ApplicationFiled: January 3, 2014Publication date: May 1, 2014Applicant: Collegium Pharmaceutical, Inc.Inventors: Jane C. HIRSH, Alison Fleming, Roman Rariy, Alexander Klibanov
-
Publication number: 20130310413Abstract: An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opioids. In one embodiment, the drug is modified to increase its lipophilicity by forming a salt between the drug and one or more fatty acids wherein the concentration of the one or more fatty acids is one to 15 times the molar amount of the active agent. The abuse-deterrent composition prevents the immediate release of a substantial portion of drug, even if the physical integrity of the formulation is compromised and the resulting material is placed in water, snorted, or swallowed. However, when administered as directed, the drug is slowly released from the composition as the composition is broken down or dissolved gradually within the GI tract by a combination of enzymatic degradation, surfactant action of bile acids, and mechanical erosion.Type: ApplicationFiled: April 25, 2013Publication date: November 21, 2013Applicant: Collegium Pharmaceutical, Inc.Inventors: Jane Hirsh, Alison Fleming, Roman Rariy, Alexander Kilbanov
-
Patent number: 8449909Abstract: An abuse-deterrent pharmaceutical composition has been developed to reduce the likelihood of improper administration of drugs, especially drugs such as opiods. In the preferred embodiment, the drug is modified to increase its lipophilicity by forming a salt between the drug and one or more fatty acids wherein the concentration of the one or more fatty acids is one to 15 times the molar amount of the active agent, preferably two to ten times the molar amount of the active agent. In one embodiment the modified drug is homogeneously dispersed within microparticles composed of a material that is either slowly soluble or not soluble in water. In some embodiments the drug containing microparticles or drug particles are coated with one or more coating layers, where at least one coating is water insoluble and preferably organic solvent insoluble.Type: GrantFiled: June 25, 2010Date of Patent: May 28, 2013Assignee: Collegium Pharmaceutical, Inc.Inventors: Jane Hirsh, Alison Fleming, Roman Rariy, Alexander Kilbanov
-
Publication number: 20090010869Abstract: Formulations are described for the treatment by enzymatic debridement of wounds and ulcers. The formulations have a clear, transparent composition that allows for easy visualization of the wound, and are non-staining for easy clean up. These formulations can also exhibit increased enzymatic debridement activity, improved post-treatment lubricity and coating occlusivity, and stability. The formulations, optionally containing non-animal source biologics, may be in the form of lotions, aerosols to provide a spray, or a foam. A non-reactive substrate may be used as a composition carrier. A non-aqueous lotion formulation having improved enzymatic activity is provided. The non-aqueous lotion viscosity is adjusted to achieve high enzymatic activity while maintaining the application benefits of high viscosity non-aqueous lotions. The lotion formulation may be delivered in a patch.Type: ApplicationFiled: August 22, 2007Publication date: January 8, 2009Inventors: Mark Trumbore, Roman Rariy, Mark Hirsh, Jane Hirsh, Julie Saunders
-
Patent number: 7345192Abstract: Compositions including a conjugate of ?-difluoromethylornithine can be applied topically to reduce hair growth.Type: GrantFiled: November 10, 2005Date of Patent: March 18, 2008Assignee: The Gillette CompanyInventors: Anwar Jardien, Roman Rariy, Gurpreet S. Ahluwalia, Douglas Shander
-
Publication number: 20080014169Abstract: Formulations are described for the treatment by enzymatic debridement of wounds and ulcers. The formulations have a clear, transparent composition that allows for easy visualization of the wound, and are non-staining for easy clean up. These formulations can also exhibit increased enzymatic debridement activity, improved post-treatment lubricity and coating occlusivity, and stability. The formulations, optionally containing non-animal source biologics, may be in the form of lotions, aerosols to provide a spray, or a foam. A non-reactive substrate may be used as a composition carrier. A non-aqueous lotion formulation having improved enzymatic activity is provided. The non-aqueous lotion viscosity is adjusted to achieve high enzymatic activity while maintaining the application benefits of high viscosity non-aqueous lotions. The lotion formulation may be delivered in a patch.Type: ApplicationFiled: August 22, 2007Publication date: January 17, 2008Inventors: Mark Trumbore, Roman Rariy, Mark Hirsh, Jane Hirsh, Julie Saunders
-
Publication number: 20070116757Abstract: Pharmaceutical compositions comprising a fatty acid salt, a dicarboxylic acid salt, an alkyl sulfate salt, an aryl sulfate salt or an alkyl aryl sulfonate salt of methylene blue or a derivative of methylene blue are described herein. The compositions are preferably administered orally and can be administered as tablets, soft or hard shell capsules (e.g. soft gelatin capsules), suspensions or solutions. The composition can also be formulated as a suppository or enema or rectal administration. The compositions further comprise a pharmaceutically acceptable carrier and optionally one or more pharmaceutically acceptable excipients. Suitable excipients include diluents, binders, plasticizers, lubricants, disintegrants, colorants, stabilizers, surfactants, and combinations thereof. The fatty acid salts, alkyl sulate salts, aryl sulfate salts or alkyl aryl sulfonate salts can be co-mixed or co-melted with one or more fatty acids to make more hydrophobic compositions, which may result in less staining formulations.Type: ApplicationFiled: November 8, 2006Publication date: May 24, 2007Inventors: Roman Rariy, Jane Hirsh
-
Publication number: 20070036843Abstract: An improved controlled release composition for non-parenteral administration of active agents and other therapeutics, particularly for oral or topical administration, has been developed. The composition is made by dispersing a complex formed of an active agent bound to an ion-exchange resin or to another form of resin or carrier, in a non-ionic non-aqueous (“NINA”) vehicle. The complexes are optionally coated with one or more layers of coating material to provide a controlled pattern of release of active agent from the carrier. Replacing the usual aqueous vehicle with a NINA vehicle, such as an oil or an ointment, allows the active agent-carrier complexes, with or without coatings, to be both orally and topically administered.Type: ApplicationFiled: January 27, 2006Publication date: February 15, 2007Inventors: Jane Hirsh, Roman Rariy, Mark Trumbore, Alison Fleming, Mark Hirsh
-
Publication number: 20060067903Abstract: Compositions including a conjugate of ?-difluoromethylomithine can be applied topically to reduce hair growth.Type: ApplicationFiled: November 10, 2005Publication date: March 30, 2006Inventors: Anwar Jardien, Roman Rariy, Gurpreet Ahluwalia, Douglas Shander
-
Patent number: 7015349Abstract: Compositions including a conjugate of ?-difluoromethylornithine can be applied topically to reduce hair growth.Type: GrantFiled: March 26, 2003Date of Patent: March 21, 2006Assignee: The Gillette CompanyInventors: Anwar Jardien, Roman Rariy, Gurpreet S. Ahluwalia, Douglas Shander